[Disease management programs: Difficulties in the analysis of benefit]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Apr;58(4-5):345-51. doi: 10.1007/s00103-015-2136-3.
[Article in German]

Abstract

After an introduction to the theme with an overview of the implementation of the Disease Management Programs (DMP), accompanying documentation, present utilization and costs of the programs, the present article is primarily devoted to the issue of the analysis of the benefits of DMP. Following an assessment of the legally specified evaluation requirements, in the absence of a prospective, randomized, controlled trial (RCT), the results of three studies are first summarized, which, with the application of propensity score matching, utilize the routine data of the statutory health insurance schemes to form a control group. The overview concludes with a look at the planned changes in evaluation and the intended expansion of the DMP to programs for other chronic illnesses.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Chronic Disease / economics*
  • Chronic Disease / therapy*
  • Cost Control / legislation & jurisprudence
  • Cost-Benefit Analysis / economics
  • Cost-Benefit Analysis / legislation & jurisprudence
  • Delivery of Health Care / economics*
  • Delivery of Health Care / legislation & jurisprudence
  • Disease Management
  • Germany
  • Health Care Costs / legislation & jurisprudence
  • Health Care Costs / statistics & numerical data*
  • Health Services Accessibility / economics*
  • Health Services Accessibility / legislation & jurisprudence
  • Humans
  • Models, Economic
  • Organizational Objectives